Drug
Canagliflozin
Canagliflozin: highest development phase Approved, developed by Aurobindo, Johnson & Johnson. 4 trial records tracked on RxWires.
- Highest phase
- Approved
- Developer
- Aurobindo, Johnson & Johnson
Trials
| Drug | Phase | Indication |
|---|---|---|
| INVOKANA | Approved | |
| CANAGLIFLOZIN | Approved | |
| INVOKAMET | Approved | |
| Canagliflozin (JNJ-28431754) NCT01759576 | Phase 1 | Renal Insufficiency |
Latest
No recent events.
Follow Canagliflozin on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.